The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

被引：19
|
作者：
Skarbnik, Alan P. [1 ]
Faderl, Stefan [2 ]
机构：
[1] Hackensack Univ, Med Ctr, Div Lymphoma, John Theurer Canc Ctr,Blood & Marrow Transplantat, 92 Second St, Hackensack, NJ 07624 USA
[2] Hackensack Univ, Med Ctr, Div Leukemia, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2017年 / 8卷 / 03期
关键词：
chemoimmunotherapy; CLL; FCR; fludarabine; rituximab; PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; INITIAL THERAPY; OPEN-LABEL; AGENT; CHLORAMBUCIL; REGIMEN; FCR; CHEMOTHERAPY; VINCRISTINE;
D O I：
10.1177/2040620716681749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia
    Mahipal, Amit
    Weiss, Mark
    CURRENT ONCOLOGY REPORTS, 2010, 12 (06) : 352 - 354
  • [42] Long-Term Survival After Fludarabine, Cyclophosphamide, and Rituximab Treatment in Previously Untreated Chronic Lymphocytic Leukemia Patients
    Mustafa, Shokhan Mohammad
    Yassin, Ahmed Khudair
    Hassan, Kawa M.
    Sadiq, Nawsherwan
    Nadihm, Marwa N.
    Abdulrahman, Lara Lateef
    Salahaden, Shlan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S263 - S264
  • [43] Long-Term Survival After Fludarabine, Cyclophosphamide, and Rituximab Treatment in Previously Untreated Chronic Lymphocytic Leukemia Patients
    Mustafa, Shokhan Mohammad
    Yassin, Ahmed Khudair
    Mohammed, Nawsherwan S.
    Shamoon, Rawand P.
    Karma, Marwa N.
    Mohammad, Shlan S.
    Abdulrahman, Lara Lateef
    Ahmed, Zhalla O.
    Rashid, Bryar Sabah
    Mahmood, Tavan I.
    Yousif, Rozhhat A.
    Hasan, Kawa M.
    Mohamed, Zaki A.
    Getta, Hisham A.
    Jalal, Sana D.
    Abdullah, Dana A.
    Abdulla, Basil K.
    Numan, Ghanim S.
    Karadagh, Ranan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S260 - S261
  • [44] Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia
    Hornberger, John
    Reyes, Carolina
    Shewade, Ashwini
    Lerner, Susan
    Friedmann, Mark
    Han, Leona
    Gutierrez, Hialy
    Satram-Hoang, Sacha
    Keating, Michael J.
    LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 225 - 234
  • [45] Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
    Assouline, Sarit
    Buccheri, Valeria
    Delmer, Alain
    Gaidano, Gianluca
    McIntyre, Christine
    Brewster, Michael
    Catalani, Olivier
    Hourcade-Potelleret, Florence
    Sayyed, Pakeeza
    Badoux, Xavier
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) : 1001 - 1009
  • [46] Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
    Byrd, John C.
    Kipps, Thomas J.
    Flinn, Ian W.
    Castro, Januaro
    Lin, Thomas S.
    Wierda, William
    Heerema, Nyla
    Woodworth, James
    Hughes, Steve
    Tangri, Shabnam
    Harris, Sarah
    Wynne, Dee
    Molina, Arturo
    Leigh, Bryan
    O'Brien, Susan
    BLOOD, 2010, 115 (03) : 489 - 495
  • [47] Relevance of the Immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
    Lin, Katherine I.
    Tam, Constantine S.
    Keating, Michael J.
    Wierda, William G.
    O'Brien, Susan
    Lerner, Susan
    Coombes, Kevin R.
    Schlette, Ellen
    Ferrajoli, Alessandra
    Barron, Lynn L.
    Kipps, Thomas J.
    Rassenti, Laura
    Faderl, Stefan
    Kantarjian, Hagop
    Abruzzo, Lynne V.
    BLOOD, 2009, 113 (14) : 3168 - 3171
  • [48] Chronic Lymphocytic Leukemia: Chemoimmunotherapy is over? No
    Eichhorst, Barbara
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S120 - S122
  • [49] Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
    Gauthier, Martin
    Durrieu, Francoise
    Martin, Elodie
    Peres, Michael
    Vergez, Francois
    Filleron, Thomas
    Oberic, Lucie
    Bijou, Fontanet
    Quillet-Mary, Anne
    Ysebaert, Loic
    BMC CANCER, 2019, 19 (01)
  • [50] Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia
    Chow, Kai Uwe
    Kim, Soo-Zin
    von Neuhoff, Nils
    Schlegelberger, Brigitte
    Stilgenbauer, Stephan
    Wunderle, Lydia
    Cordes, Hans-Joerg
    Bergmann, Lothar
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (05) : 426 - 433
12345